CMPS

#2642
COMPASS Pathways Plc American Depository Shares
5.8501 USD
+1.39%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
5.8450
5.8600
Rango anual
4.8800
8.9000
Cambio diario
+1.39%
Variación mensual
-9.02%
Variación en los últimos 6 meses
-8.16%
Cambio anual
-8.16%
Cierres anteriores
5.7700
Abrir
5.8450
Bid
Ask
Mínimo
5.8450
High
5.8600
Volumen
39
Ver el calendario completo

Financials

Visión general Informes Estadísticas
Trimestre Año
Informe de resultados Saldo Flujo de caja
Valor 202020212022202320242025 TTM

COMPASS Pathways Plc - American Depository Shares

Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin, is currently in phase 3 clinical trials for treatment-resistant depression. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration. It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine. Compass Pathways is the largest company in the psychedelic medicine industry and, in 2020, was the first psychedelic medicine company to be listed on the NASDAQ. It has faced criticism for patenting psychedelic drugs and even certain psilocybin mushroom species. In October 2024, after the FDA rejected Lykos Therapeutics's MDMA for post-traumatic stress disorder New Drug Application, Compass Pathways said that it would lay off 30% of its workforce and narrow its research focus. Compass Pathways has entered partnerships with several independent psychedelic academic scientists, including Jason Wallach, Hamilton Morris, and Adam Halberstadt among others, to develop novel psychedelic drugs for potential medical use.

Noticias